Immunotherapy for cardiovascular disease

Esther Lutgens, Dorothee Atzler, Yvonne Doering, Johan Duchene, Sabine Steffens, Christian Weber*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

62 Citations (Web of Science)

Abstract

The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1 beta antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.

Original languageEnglish
Pages (from-to)3937-3946
Number of pages13
JournalEuropean Heart Journal
Volume40
Issue number48
DOIs
Publication statusPublished - 21 Dec 2019

Keywords

  • Cardiovascular disease
  • Coronary artery disease
  • Inflammation
  • Novel therapies
  • Novel targets
  • Cytokines
  • CONGESTIVE-HEART-FAILURE
  • MYOCARDIAL-INFARCTION
  • PREVENTS ATHEROSCLEROSIS
  • PROMOTES ATHEROSCLEROSIS
  • COSTIMULATORY MOLECULES
  • MACROPHAGE PHENOTYPE
  • PLATELET CHEMOKINES
  • NLRP3 INFLAMMASOME
  • BIOLOGICAL BASIS
  • DEFICIENCY

Cite this